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Abstract
Alzheimer’s disease is a degenerative brain disease which impairs a person’s
ability to perform day to day activities. Research has shown AD to be a
heterogeneous condition, having a high variation in terms of the symptoms
and disease progression rate. Treating Alzheimer’s disease (AD) is especially
challenging due to these variations present in the disease progression stages.
The clinical symptoms of AD show marked variability in terms of patients’
age, disease span, progression velocity and types of memory, cognitive and
depression related features. Hence, the idea of personalized clinical care,
with individualized risk, progression and prediction related patient advice in
AD is narrow. This facilitates the yet unfulfilled need for an early prediction
of the disease course to assist its treatment and tailor therapy options to
the progression rate. Additionally, there are ramifications in clinical trial
design when considering the high heterogeneity of disease manifestation and
progression.
Recent developments in machine learning techniques provide a huge po-
tential, not only to predict the onset and progression of Alzheimer’s disease
but also to classify the disease into different etiological subtypes. The ad-
vancement of these prediction models have the potential to impact clinical
decision making and improve healthcare resource allocation. It will also lead
to the development of personalized clinical care and counseling for patients,
hopefully reducing AD treatment costs.
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The suggested work clusters patients in distinct and multifaceted progres-
sion subgroups of Alzheimer’s disease and discusses an approach to predict
the progression stage from baseline diagnosis through the implementation of
machine learning techniques. By applying machine learning algorithms on
the extensive clinical observations available in the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) dataset, we parse the progression space for the
Alzheimer’s disease into low, moderate and high disease progressors. This
work suggests that the myriad of clinically reported symptoms we summarize
in the Alzheimer’s Disease progression space correspond directly to memory
and cognition measurements classically used to monitor disease onset and
progression. The proposed work concludes notably accurate prediction of
disease progression after four years from the first 12 months of post-diagnosis
data (area under receiver operating characteristic (ROC) curve of 0.90 ± 0.02
for Controls, 0.96 ± 0.04 for High rate, 0.90 ± 0.04 for Moderate rate 0.83 ±
0.06 for Low rate). We validate our model through five-fold cross-validation
to obtain a robust prediction of membership into these progression subtypes.
These machine learning techniques will assist the medical practitioners to
classify different progression rates within patients and allow for more efficient
and unique care delivery. With additional information about the onset rate
of AD at hand, doctors may alter their treatments to better suit the patients.
The predictive tests discussed in this report not only allow for early detection
but also facilitate the characterization of distinct disease subtypes relating
to trajectories of disease progression. This will lead to improved clinical trial
design and reducing skyrocketing healthcare costs in the future.
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Alzheimer’s disease (AD), is an irreversible and age-associated neurodegen-
erative disease, progressively affecting memory, intellectual skills and other
mental functions. It is the most common form of dementia. After the age
of 65, the prevalence of dementia doubles every 5 years and it increases ex-
ponentially after the age of 90 [1]. As dementia affects older people, with
growing life expectancy it is becoming a major medical problem [2].
With no preventive intervention, disease progression is a major concern for
doctors around the globe. Researchers have shown that AD initiates 10-15
years before the actual disease symptoms are observed in AD patients. In
the absence of any cure for AD there are some treatments available to de-
lay the advancement of disorder. With the delay in the diagnosis of AD its
severity increases therefore, early detection of AD onset and progression rate
is very important. A major challenge for AD prediction is this presence of
inherent phenotypic diversity in the AD population. Identifying disease pro-
gression trajectories at an early stage will help in designing disease-modifying
treatment strategies for Alzheimer’s disease.
For the treatments to be most effective, the regimen must likely begin
before the notable downstream damage. Simply put, early detection is a
likely scenario to make the greatest therapeutic gains. Mild cognitive im-
pairment (MCI) patients are at a higher risk of progressing to dementia, but
not all the patients end up developing AD [3]. Research has been done to
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detect AD in patients with MCI or predict the early stage of Alzheimer’s
disease using cerebrospinal fluid (CSF) [4], [5], while others [6] have used
psychometric and imaging data for predicting the progression of dementia
in patients with amnestic mild cognitive impairment. In the implementation
of the multiclass classifier which uses clinical data along with image data to
classify Alzheimer’s disease, MCI patients and controls gave an accuracy of
79.8% [7]. Less work has been done on using just clinical data and predicting
the Alzheimer’s disease progression rate. Faraz et. al. in [8] used machine
learning to classify Parkinson’s disease (PD) patients into three different sub-
categories with highly predictable progression rates. They explored variation
in onset age, progression velocity and further observed clusters of motor, cog-
nitive and sleep disturbance related features using the clinical test datasets.
We propose to validate the approach used by Faraz Faghri et. al. [8] by
applying it to the clinical features of the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) dataset.
This work clusters patients in distinct progression groups of Alzheimer’s
disease and discusses an approach to predict the progression stage in an early
baseline period. Dimensionality reduction was used to define a “progres-
sion space” for the Alzheimer’s disease summarizing myriad clinical mea-
sures across multiple time points. Our work suggests that the clinically
related symptoms summarizing the Alzheimer’s Disease progression space





2.1 Study design and participants
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary goal of ADNI has been
to test whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neuropsycho-
logical assessment can be combined to measure the progression of mild cog-
nitive impairment (MCI) and early Alzheimer’s disease (AD). For up-to-date
information, see www.adni-info.org.
Predictions were made using baseline with up to 12 months of data, for
each patients position after 24 and 48 months. The proposed study consist
of 453 observation (with 208 (45.92%) female observations, average age for
all participants is 72.32 ± 7.13 years, 93.59 % of them are of European
ancestry) for prediction at 24th month and 247 observations (with 123 (49.79
%) female observations, average age for all participants is 71.55 ± 6.79 years,
94.73 % of them are of European ancestry) for prediction at 48th month. For
observations corresponding to 24th month mean age is 72.84 ± 6.09, 71.61 ±
7.47 and 72.92 ± 8.11 corresponding to Controls, MCI and dementia patients.
Whereas for observations corresponding to 48th month the mean age is 72.17
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± 6.67, 71.36 ± 6.67 and 70.34 ± 7.42 corresponding to Control, MCI and
dementia patients.
The features from the following longitudinally collected common data ele-
ments were used in the proposed work:
1. Montreal Cognitive Assessment (moca) [9]
2. Clinical Dementia Rating (cdr) [10]
3. Neuropsychiatric Inventory (npi) [11]
4. Neuropsychological Battery (neurobat) [11]
5. Mini Mental State Exam (mmse) [12]
6. Geriatric depression scale (gd scale/geriatric) [13]
7. Everyday cognition - study partner (ecogsp) [14]
8. Everyday cognition - participant (ecogpt) [14]
9. Functional Assessment Questionnaire (faq) [15]
There are 145 unique features in the above data set. If we consider a feature
for different visits as separate feature then there are 417 features. During
the analysis some features were reduced to one feature and this changed the
total number of features from 417 to 213. An elaborated list of features used
in each test with their definition is given in the supplementary material.
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2.2 Procedures and statistical analysis
To motivate replication of the study, the Python code is made available in
the supplementary material. Only the observations which had data recorded
for all the considered tests were taken into account. To construct the pro-
gression space we have used readings taken at baseline and after 6 and 12
months from baseline. Readings taken for any feature during the different
visit was considered as a separate feature. To cope with the missing data
we have leveraged the temporal nature of the data. Missing value for any
feature was imputed using linear interpolation based on past or future visit
readings of the same feature. Because of this, we were able to avoid any
influence of other observations in the data during data imputation. For some
observations there were not enough readings available for linear interpola-
tion. These observations were excluded from further analysis, therefore after
the imputation around 7 % data was reduced. For categorical variables one
hot encoding was used as necessary. Scaling the continuous features to a
comparable range is necessary to avoid the influence of certain features over
others. Min-max normalization was used to retain progressions since the
ADNI dataset in consideration is multimodal. Furthermore, Min-max Nor-
malization will not change categorical features. Figure 2.1 shows the steps
followed during the model development.
To reduce the dimensionality of the dataset, non-negative Matrix Factor-
ization (NMF) [16] (with a rank of 2) was used on 582 observations which
had data available for baseline, 6th and 12th month visit. We used NMF to
deconstruct data into two matrices, namely progression vectors and the pro-
gression indicators which corresponds to latent vectors. Progression vectors
are used to construct a 2-dimensional progression space. This 2-dimensional
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space was used to predict the patient’s disease progression stage after 24
and 48 months from baseline. Disease progression stage after 18 months was
not predicted as very few observations had labels available at this time point.
Progression indicators map the features in the original dataset to the progres-
sion space, which enable us to identify dimensions of the modeled progression
space. Through the use of NMF, we were able to identify memory decline
and cognitive decline as the two dimensions of the progression space.
Figure 2.1: Workflow of analysis and model development.
Gaussian mixture model (GMM) [17] is a latent variable model that is
used for unsupervised clustering. This model postulates that the observed
data is comprised of different clusters and the distribution within each cluster
is a Gaussian. It is implemented using expectation maximization algorithm
which maximizes the likelihood of observing the data, given the underly-
ing parameters of the distribution. GMM was used to find clusters in MCI
and dementia patients. Since the number of underlying clusters needs to
be specified for GMM, Bayesian Information Criterion (BIC) [18] was used
to select the optimum number of clusters. BIC is a Maximum Likelihood
Estimate which tries to select the best model among the given set of candi-
dates. In all the cases, 3 was the optimum number of clusters (which were
classified as low, moderate and high progression rate). After obtaining a
progression space and classifying MCI and dementia patients into different
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progression groups, the performance of various supervised learning classifiers
(ensemble random forest, linear discriminant analysis, naive bayes, adaptive
boosting, nearest neighbors, logistic regression and decision trees) was com-
pared to predict a patient’s progression. The random forest classifier gives
best five-fold cross-validation accuracy. Parameters for Random Forest Al-
gorithm [19] were fine-tuned using grid search (1944 iterations) and five-fold
cross-validation accuracy. Two models were built a) Model 1: predict pro-
gression at 24th month after baseline by using baseline and first year factors
b) Model 2: predict progression at 48th month after baseline by using baseline




Two different evaluation metrics were used for validating the clustering and
prediction. The area under the receiver operating characteristic curve was
used to evaluate clustering. Sensitivity and specificity are the measures of
the proportion of positives that are correctly identified and negatives that
are correctly identified respectively. The plot of sensitivity on y-axis and
1-specificity on x-axis is called the receiver operating characteristic curve
with a greater value representing a better clustering model. Since this is a
multiclass problem one vs all approach was used to calculate the area under
receiver operating characteristic for each class. Since the explored ADNI
dataset has a small number of patients five-fold cross-validation was used to
judge the proposed prediction model. The model was trained on four parts




To reduce the dimensionality of the data Non-negative Matrix Factorization
(NMF) was used, which decomposes the dataset into progression vectors and
progression indicator vectors. These progression vectors were used to project
the patients’ disease progression stage at the 24th Figure 4.2 and 48th month
Figure 4.3 . The progression indicator vectors i.e. coefficient Matrix obtained
from the NMF was used to find out the latent features that each of the two
axes of the reduced space represents.
The reduced progression space is 2 dimensional, so we have 2 progression
indicator vectors. Progression indicator vectors represent the latent features
of reduced progression space. The features observed in the real data were
correlated to the 2 axes of progression space using this magnitude of coef-
ficients observed in the progression indicator vectors. A higher magnitude
corresponding to the first progression indicator vector will correlate the fea-
ture to the first axis and similarly a higher magnitude corresponding to the
second progression indicator vector will correlate the feature to the second
axis. Progression indicator coefficients for each feature are plotted in Figure
4.1 and they are separated by drawing a line with slope 1. Features which
fall below this separating line were associated with the x-axis (cognitive de-
cline) in projection space and features which lie above the separating line
were associated with the y-axis (memory Decline) of progression space. Fea-
tures which lie close to the separating line were not associated with any axis.
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Associated axis for each feature is shown in Table C.1 in the appendix.
Figure 4.1: Plot of features in 2 dimensions using progression indicator
vectors. Features in red corresponds to memory decline and features in blue
corresponds to cognitive decline. Yellow line with slope of 1 is drawn for
reference which separates the features into two categories.
The progression rate of patients after 24th and 48th months from the base-
line were predicted using the Random forest classifier. It gave the best five-
fold cross-validation accuracy and area under the receiver operating char-
acteristic curve results for all the cases. For the prediction of progression
at 24th month using baseline and 12 months of observation area under the
receiver operating characteristic curve is 0.94±0.03. for controls, 0.98±0.01
for high progression rate, 0.90±0.05 for low progression rate and 0.94±0.03
for moderate progression rate. Prediction of progression at 48th month us-
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Figure 4.2: Left: Progression rate of 453 cases/observations are projected
in the Alzheimer’s Disease Progression Space at 24th month. Low,
medium/moderate, high are represented in yellow, blue and pink
respectively. Right: 453 cases/observations are projected in the
Alzheimer’s Disease Progression Space at 24th month. Controls are
represented in red, MCI in blue and dementia in green.
ing baseline and 12 months of observation yields area under the receiver
operating characteristic curve of 0.90±0.02 for controls, 0.96±0.04 for high
progression rate, 0.83±0.06 for low progression rate and 0.90±0.04 for mod-
erate progression rate. In our implementation, the five-fold cross-validation
accuracy for prediction of progression at the 24th and 48th month is 84.98%
and 79.75% respectively.
These results are also presented in Table 4.1. Figure 4.6 and Figure 4.7 are
receiver operating characteristic curves for 4 separate classes (controls, low,
moderate and high progression rate) for 24th and 48th month respectively.
Apolipoprotein E (APOE) comes in three variants namely 2, 3, and 4, out
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Figure 4.3: Left: Progression rate of 248 cases/observations are projected
in the Alzheimer’s Disease Progression Space at 48th month. Low,
medium/moderate, high are represented in yellow, blue and pink
respectively. Right: Total 248 cases/observations are projected in the
Alzheimer’s Disease Progression Space at 48th month. Controls are
represented in red, MCI in blue and dementia in green.
of which the APOE4 gene variant is closely associated with a higher risk of
Alzheimer’s disease [20]. Distribution of APOE4 variants after 24 months
in each subtype is shown in the Figure 4.8. It shows the share of different
APOE4 variant for every progression rate. As evident from the Figure 4.8
the share of 1 and 2 occurrences of APOE4 variant goes on increasing with
progression rate whereas the share of 0 occurrences APOE4 variants goes on
decreasing. Count of each 0, 1 and 2 occurrences of APOE4 variants after
24 months in each progression rate is shown in Table 4.2.
Number of controls, MCI and dementia patients in each subtype after 24
months is shown in Table 4.3. Figure C.6 shows the share percentage of
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Figure 4.4: Three different progression rates are identified in MCI and
dementia patients at 24th month. In this figure low progression rate zone is
represented in red, moderate progression rate in blue and high progression
rate in green.
controls, MCI and dementia patients in each of the subtypes present after 24
months from baseline. As expected the share of dementia patient is maxi-
mum in high progression rate. Low progression rate has the lowest share of
dementia patients and the highest share of MCI patients. Moderate progres-
sion rate subtype is dominated by MCI patients, which covers around 62%
of the observation in that subtype.
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Figure 4.5: Three different progression rates are identified in MCI and
dementia patients at 48th month. In this figure low progression rate zone is











M24 84.98±5.45 0.94±0.03 0.90±0.05 0.94±0.03 0.98±0.01
M48 79.75±4.25 0.90±0.02 0.83±0.06 0.90±0.04 0.96±0.04
Table 4.1: Results for model 1 and model 2
APOE4 Control Low Moderate High Total
0 123 79 42 14 258
1 44 37 54 20 155
3 3 9 15 13 40
Table 4.2: Count of 0, 1 and 2 occurrences of APOE4 after 24 month for
different progression rate
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Figure 4.6: Area under ROC curve for each individual class. The
predictions for disease stage at 24th month were made using Random Forest
Algorithm.
Figure 4.7: Area under ROC curve for each individual class. The
predictions for disease stage at 48th month were made using Random Forest
Algorithm.
Low Moderate High
MCI 60 30 8
Dementia 2 12 26
Table 4.3: Count of MCI and dementia patients after 24 month in each
subtype
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Figure 4.8: Percent share of APOE4 variants for different subtypes after 24
months from baseline.
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Figure 4.9: Percent share of controls, MCI and dementia patients for




Since ADNI is a longitudinal study, the disease state of patients are reassessed
every 12 months. Condition for most of the patients either deteriorated or
stayed the same but in rare cases, it reversed to a better state i.e. some pa-
tients were observed moving from dementia to MCI or MCI to control stage.
These observations were plotted to access the robustness of the progression
space. Figure 5.1 and Figure 5.2 plots these reversion cases. It can be veri-
fied from these figures that patients moving from dementia to MCI fall in the
intermediate region between dementia and MCI (moderate progression rate
region). Thus progression space captures the reversion of disease state. Sim-
ilarly, patients moving from MCI to control lie in intermediate progression
region between them as seen in Figure 5.1 and Figure 5.2.
As stated earlier Alzheimer’s disease risk is associated with APOE4 gene
variants [20]. Progression space was constructed using only time-variant clin-
ical data. Therefore, APOE4 data wasn’t considered during the construction
of the projection space. In order to understand underlying biological pat-
terns among patients in the progression space, we plotted distribution of the
APOE4 variants. Figure 5.3 and Figure 5.4 projects the observations with 0
and 2 counts of APOE4 variants on the AD progression space. As evident
from them, observations with 0 count of APOE4 variant are concentrated
towards the low progression rate zone, whereas observations with 2 counts
of APOE4 variant are concentrated towards moderate and high progression
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Figure 5.1: Figure represent positions of the reversions (only MCI to control
and dementia to MCI) at 24th month relative to all other observations.
rate zones. This observation is validated by the existing literature which
has identified a significant correlation between APOE4 genetic variants and
cognitive performance [21].
In Figure 5.5 and Figure 5.6 progression can also be seen in control ob-
servations at 24th and 48th month respectively which is attributed to decline
in normal cognition and memory with increasing age. Since this decline is
not severe, the observations do not lie in moderate or high progression rate
zones. A simple clustering of observations into two clusters shows a stark
difference in the mean age of the clusters. For the projection corresponding
to the 24th month, the mean age of the observations which lie in the cluster
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Figure 5.2: Figure represent positions of the reversions (only MCI to control
and dementia to MCI) at 48th month relative to all other observations.
which is relatively close to the moderate progression rate zone is 74.59 years
and the mean age of the observations which lie in the cluster which is away
from the moderate progression rate zone is 72.15 years. For the projection
corresponding to the 48th month, the mean age of the observations which lie
in the cluster which is relatively close to the moderate progression rate zone
is 73.51 years and the mean age of the observations which lie in the cluster
which is away from the moderate progression rate zone is 71.53 years.
To find out the general trend in the progression rate, a polynomial curve
was fit on the projected observations. Bayesian Information Criterion (BIC)
[18] was used to find out the optimum degree of the polynomial to fit the
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Figure 5.3: Projection of number of APOE4 variants on the projection
space at 24th month. X-axis and y-axis have visualizations of distribution of
APOE4 variants in those direction.
curve, which was observed to be three. As seen in the Figure 5.7, cubic
curve fits the data in a linear fashion in low progression region. However, it
deviates slightly from this linear behavior in high and moderate progression
region. The magnitude of the slope of the linear curve is 1.19 indicating a
rapid memory decline as compared to cognitive decline. Research work [22]
has established a link between education and memory decline in Alzheimer’s
disease. In their research memory declined more rapidly in AD patients with
higher educational and occupational attainment. The slope of the progression
for 200 most and least educated observations is plotted in the Figure 5.8. The
magnitude of slope for the linear curve is 1.26 and 1.19 for highly educated
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Figure 5.4: Projection of number of APOE4 variants on the projection
space at 48th month. X-axis and y-axis have visualizations of distribution of
APOE4 variants in those direction.
and less educated patients respectively. As slope for highly educated patients
is greater than the slope for less educated patients there is a relatively rapid
decline in memory of patients with high education. This is validated by
previous research [22] done in this field.
Figure 5.9 and Figure 5.10 shows the distribution of projected dimensions
( memory decline and cognitive decline) for each AD subtype after 24 and 48
months respectively. In the progression space, along the positive direction
of y-axis, the memory decline increases and along the negative direction of
x-axis the cognitive decline increases. A low value on x-axis indicates higher
cognitive decline whereas a high value on y-axis indicates higher memory
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Figure 5.5: The mean age of cases/observations in the two clusters of
controls. Clusters represent aging pattern in controls at 24th month. The
cluster near moderate progression rate zone has a higher mean age than one
which is away from it.
decline. High progression rate has the highest memory and cognitive de-
cline, which goes on reducing with a reduction in progression rate. Figure
5.11 shows distribution of MMSE score after 6 and 12 months for each sub-
type at 24th month. Reduction in MMSE score with increased progression
is observed. There is an increase in the FAQ (Functional Assessment Ques-
tionnaire) total score with increasing progression rate as shown in Figure
5.12.
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Figure 5.6: The mean age of cases/observations in the two clusters of
controls. Clusters represent aging pattern in controls at 48th month. The
cluster near moderate progression rate zone has a higher mean age than one
which is away from it.
24
Figure 5.7: Linear and cubic curve fitting on 582 cases/observations
projected on the progression space.
25
Figure 5.8: Linear curve fitting for 200 most educated and 200 least
educated cases/observations.
26
Figure 5.9: The distribution of projected dimensions (cognitive and
memory decline) for each AD subtype after 24 months from baseline. High
progression rate subtype has the highest cognitive and memory decline.
27
Figure 5.10: The distribution of projected dimensions (cognitive and
memory decline) for each AD subtype after 48 months from baseline. High
progression rate subtype has the highest cognitive and memory decline.
28
Figure 5.11: The distribution of MMSE score for each AD subtype
(subtypes at 24th month). MMSE score decreases with increase in
progression rate.
29
Figure 5.12: The distribution of Functional Assessment Questionnaire
(FAQ) total score for each AD subtype (subtypes at 24th month). It




This work clusters patients in distinct progression stages of Alzheimer’s dis-
ease and discusses an approach to predict the future rate of progression after
24th and 48th months from baseline. Predicting disease progression serves
as a paramount challenge in the therapy and cure of several elaborate dis-
eases. Predicting AD progression rates would lead to attention being drawn
to patients by recognizing at an early stage the patients with a swift rate of
progression. The developed prediction algorithms can help doctors and prac-
titioners develop a methodical and organized course for clinical tests, which
can be much more concise and effective in detection. These adaptations and
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Appendix A: Python code for replication of
study
The supplementary file ADNI 24 MONTH ANALYSIS.ipynb contains the
code required for replication of study. Part 1 of the code contains code
for descriptive analysis of ADNI data (24 months considered). Part 2 of
code contains code for predictive analysis of ADNI data (predictions for low,
moderate,high progression rate at 24th month).
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Appendix B: Table with description of features
The supplementary file FEATURE DESCRIPTION TABLE.xlsx contains
description of all the features used in this study.
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Appendix C: Additional table and figures
Table C.1: Axis labels for features using 2D NMF and Gaussian Mixture
Model
Dataset Feature Visit Axis Assigned
ecogsp memory m12 y-axis
ecogsp memory m06 y-axis
ecogsp division m12 y-axis
ecogsp memory bl y-axis
ecogsp division m06 y-axis
ecogsp org m12 y-axis
neurobat COPYSCOR bl x-axis
neurobat COPYSCOR m06 x-axis
ecogsp division bl y-axis
moca moca naming m06 x-axis
moca moca naming bl x-axis
ecogsp org m06 y-axis
neurobat COPYSCOR m12 x-axis
moca moca naming m12 x-axis
cdr CDMEMORY m12 y-axis
ecogsp plan m12 y-axis
moca moca immediate recall bl x-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
ecogsp lang m12 y-axis
neurobat TRABSCOR m12 y-axis
cdr CDMEMORY m06 y-axis
ecogsp plan m06 y-axis
ecogsp org bl y-axis
moca moca immediate recall m12 x-axis
neurobat TRABSCOR m06 y-axis
ecogsp lang m06 y-axis
cdr CDJUDGE m12 y-axis
cdr CDORIENT m12 y-axis
ecogsp vis m12 y-axis
neurobat CLOCKSCOR m06 x-axis
cdr CDCOMMUN m12 y-axis
cdr CDORIENT m06 y-axis
neurobat TRABSCOR bl y-axis
moca moca orientation bl x-axis
ecogsp lang bl y-axis
moca moca orientation m06 x-axis
ecogsp plan bl y-axis
cdr CDCOMMUN m06 y-axis
moca moca trail making m06 x-axis
moca moca abstraction m06 x-axis
moca moca immediate recall m06 x-axis
neurobat BNTSPONT m12 x-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
ecogsp vis m06 y-axis
ecogpt memory bl y-axis
neurobat BNTSPONT m06 x-axis
neurobat CLOCKSCOR bl x-axis
moca moca visuosoconstructional bl x-axis
moca moca abstraction bl x-axis
neurobat BNTSPONT bl x-axis
moca moca orientation m12 x-axis
ecogpt memory m06 y-axis
moca moca sen repetetion bl x-axis
FAQ FAQTOTAL m12 y-axis
ecogpt memory m12 y-axis
moca moca abstraction m12 x-axis
mmse MMSCORE m12 x-axis
neurobat CLOCKSCOR m12 x-axis
moca moca visuosoconstructional m06 x-axis
mmse MMSCORE m06 x-axis
cdr CDHOME m12 y-axis
ecogsp vis bl y-axis
FAQ FAQTOTAL m06 y-axis
moca moca trail making bl x-axis
moca moca delayed word recall m06 x-axis
moca moca delayed word recall bl x-axis
moca moca trail making m12 x-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
moca moca sen repetetion m06 x-axis
moca moca visuosoconstructional m12 x-axis
moca moca sen repetetion m12 x-axis
cdr CDHOME m06 y-axis
moca moca delayed word recall m12 x-axis
FAQ FAQTOTAL bl y-axis
ecogpt division bl y-axis
ecogpt division m12 y-axis
ecogpt division m06 y-axis
neurobat TRAASCOR m12 y-axis
ecogpt lang bl y-axis
ecogpt lang m06 y-axis
neurobat BNTPHON m12 y-axis
neurobat AVDELTOT bl x-axis
moca moca fluency bl x-axis
ecogpt lang m12 y-axis
ecogpt org m06 y-axis
ecogpt org m12 y-axis
moca moca fluency m06 x-axis
neurobat BNTPHON m06 y-axis
neurobat TRAASCOR m06 y-axis
ecogpt org bl y-axis
neurobat TRAASCOR bl y-axis
ecogpt plan m06 y-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
ecogpt plan m12 y-axis
neurobat AVDELTOT m06 x-axis
neurobat BNTPHON bl y-axis
ecogpt plan bl y-axis
neurobat AVDELERR2 m12 y-axis
moca moca fluency m12 x-axis
ecogpt vis bl y-axis
ecogpt vis m06 y-axis
neurobat AVDELTOT m12 x-axis
ecogpt vis m12 y-axis
neurobat AVDELERR2 m06 y-axis
neurobat TRABERRCOM m06 y-axis
neurobat AVERRB m12 y-axis
moca moca attention bl x-axis
moca moca attention m06 x-axis
moca moca attention m12 x-axis
neurobat AVDELERR2 bl y-axis
neurobat AVERRB m06 y-axis
neurobat TRABERRCOM bl y-axis
npi all NPIGTOT bl y-axis
gd scale GDTOTAL m12 y-axis
neurobat CATANIMSC m06 x-axis
npi all NPIGTOT m12 y-axis
gd scale GDTOTAL m06 y-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
neurobat CATANPERS m12 y-axis
neurobat AVTOT1 bl x-axis
neurobat BNTSTIM bl y-axis
neurobat BNTSTIM m06 y-axis
neurobat CATANIMSC m12 x-axis
neurobat BNTSTIM m12 y-axis
neurobat CATANPERS bl y-axis
neurobat AVTOT2 bl x-axis
neurobat AVTOT2 m06 x-axis
neurobat AVTOT3 m06 x-axis
neurobat TRABERROM m12 y-axis
neurobat CATANIMSC bl x-axis
npi all NPIDTOT m12 y-axis
neurobat AVTOT5 m06 x-axis
neurobat AVTOT1 m06 x-axis
neurobat AVTOTB m06 x-axis
neurobat AVERRB bl y-axis
neurobat AVTOT4 m12 x-axis
npi all NPILTOT m12 y-axis
neurobat AVTOT2 m12 x-axis
npi all NPIITOT bl y-axis
neurobat AVTOT3 m12 x-axis
npi all NPICTOT m12 y-axis
neurobat TRABERRCOM m12 y-axis
42
Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
neurobat BNTCPHON m12 y-axis
npi all NPIITOT m12 y-axis
neurobat CATANPERS m06 y-axis
neurobat AVTOTB bl x-axis
neurobat AVTOT1 m12 x-axis
npi all NPIETOT bl y-axis
npi all NPICTOT bl y-axis
npi all NPIDTOT bl y-axis
neurobat BNTCPHON m06 y-axis
neurobat AVTOT5 bl x-axis
neurobat BNTCPHON bl y-axis
neurobat AVTOT4 m06 x-axis
neurobat TRABERROM m06 y-axis
neurobat AVERR1 m06 y-axis
neurobat AVERR3 m06 y-axis
npi all NPIETOT m12 y-axis
neurobat AVERR5 m06 y-axis
neurobat AVTOT4 bl x-axis
neurobat AVDELERR1 bl x-axis
neurobat AVTOTB m12 x-axis
neurobat AVTOT5 m12 x-axis
npi all NPIKTOT bl y-axis
neurobat AVERR1 bl y-axis
neurobat AVTOT3 bl x-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
npi all NPIKTOT m12 y-axis
neurobat AVERR5 bl y-axis
npi all NPILTOT bl y-axis
neurobat TRABERROM bl y-axis
neurobat TRAAERRCOM bl y-axis
neurobat AVERR4 bl y-axis
neurobat AVERR2 m06 y-axis
neurobat AVDELERR1 m06 x-axis
neurobat AVERR4 m06 y-axis
npi all NPIJTOT m12 y-axis
neurobat AVERR4 m12 y-axis
neurobat AVERR3 m12 y-axis
npi all NPIJTOT bl y-axis
neurobat AVERR5 m12 y-axis
npi all NPIHTOT m12 y-axis
npi all NPIHTOT bl y-axis
neurobat TRAAERRCOM m06 y-axis
neurobat AVERR3 bl y-axis
npi all NPIATOT m12 y-axis
neurobat LIMMTOTAL m12 x-axis
neurobat TRAAERRCOM m12 y-axis
neurobat AVDELERR1 m12 x-axis
npi all NPIATOT bl y-axis
neurobat TRAAERROM m12 y-axis
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Table C.1 continued from previous page
Dataset Feature Visit Axis Assigned
neurobat CATANINTR bl y-axis
npi all NPIFTOT bl y-axis
npi all NPIBTOT bl y-axis
npi all NPIBTOT m12 y-axis
npi all NPIFTOT m12 y-axis
neurobat TRAAERROM m06 y-axis
neurobat TRAAERROM bl y-axis
neurobat AVDEL30MIN m06 x-axis
neurobat AVDEL30MIN bl x-axis
neurobat AVDEL30MIN m12 x-axis
neurobat AVTOT6 m12 x-axis
neurobat AVTOT6 m06 x-axis
neurobat AVTOT6 bl x-axis
neurobat LDELTOTAL m12 x-axis
45


















































































































Figure C.1: Projection mapping for clinical features to new 2D AD
progression space axis. Here first axis corresponds to cognition related
features and second axis corresponds to memory related features.
46
Figure C.2: Number of observations available for each feature before and
after imputation.
47
Figure C.3: The distribution of MMSE score for each AD subtype (subtypes
at 48th month). MMSE score decreases with increase in progression rate.
48
Figure C.4: The distribution of Functional Assessment Questionnaire
(FAQ) total score for each AD subtype (subtypes at 48th month). It
increases with increase in progression rate.
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Figure C.5: Percent share of APOE4 variants for different subtypes after 48
months from baseline.
50
Figure C.6: Percent share of controls, MCI and dementia patients for
different subtypes present after 48 months from baseline.
51
F
ig
u
re
C
.7
:
C
om
p
ar
is
on
of
d
iff
er
en
t
al
go
ri
th
m
s
fo
r
th
e
p
re
d
ic
ti
on
of
p
ro
gr
es
si
on
af
te
r
24
m
on
th
s
fr
om
th
e
b
as
el
in
e.
F
iv
e-
fo
ld
cr
os
s-
va
li
d
at
io
n
ac
cu
ra
cy
w
as
u
se
d
to
ev
al
u
at
e
ea
ch
m
o
d
el
.
R
an
d
om
F
or
es
t
al
go
ri
th
m
p
ro
v
id
es
th
e
h
ig
h
es
t
ac
cu
ra
cy
.
52
F
ig
u
re
C
.8
:
C
om
p
ar
is
on
of
d
iff
er
en
t
al
go
ri
th
m
s
fo
r
th
e
p
re
d
ic
ti
on
of
p
ro
gr
es
si
on
af
te
r
48
m
on
th
s
fr
om
th
e
b
as
el
in
e.
F
iv
e-
fo
ld
cr
os
s-
va
li
d
at
io
n
ac
cu
ra
cy
w
as
u
se
d
to
ev
al
u
at
e
ea
ch
m
o
d
el
.
R
an
d
om
F
or
es
t
al
go
ri
th
m
p
ro
v
id
es
th
e
h
ig
h
es
t
ac
cu
ra
cy
.
53
